

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Acotec Scientific Holdings Limited**  
**先瑞達醫療科技控股有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 6669)**

**VOLUNTARY ANNOUNCEMENT**  
**APPROVAL FOR VERICOR® BY U.S. FDA**

This announcement is made by Acotec Scientific Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that on November 7, 2022, the Group received the section 510(k) registration approvals from the U.S. Food and Drug Administration (the “**U.S. FDA**”) for Vericor®, a peripheral support catheter designed to enhance access to peripheral vessels. Vericor® is used together with guidewires to recanalize chronic total occlusion (CTO) lesions, above-the-knee (ATK) lesions and below-the-knee (“**BTK**”) lesions and to reduce the difficulty of performing surgeries on complex lesions and BTK lesions. The Company will carry out marketing activities when appropriate.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET VERICOR® SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By Order of the Board  
**Acotec Scientific Holdings Limited**  
**Jing LI**  
*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, November 11, 2022

*As at the date of this announcement, the executive Directors are Ms. Jing LI and Mr. Silvio Rudolf SCHAFFNER, the non-executive Directors are Mr. Ke TANG and Mr. Chen CHEN, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.*